Key takeaways for Nevada
- • Insulin resistance is not a labeled FDA indication for any GLP-1.
- • Improvements typically substantial (30-50% HOMA-IR reduction).
- • Treat via parent diagnosis (obesity, PCOS, T2D, prediabetes).
- • Nevada Medicaid coverage rules apply for Insulin Resistance patients in Nevada — see Medicaid section below.
- • 13 GLP-1 telehealth providers available nationwide.
Why GLP-1 medications for Insulin Resistance
There is no FDA indication for insulin resistance as a standalone diagnosis — it is a physiological state, not a labeled disease. GLP-1 therapy improves insulin sensitivity through weight loss, slowed gastric emptying, glucagon suppression, and beta-cell function preservation. Evidence grade: B. Patients with insulin resistance are typically treated via comorbid diagnoses (obesity, prediabetes, PCOS, T2D). HOMA-IR scores typically improve 30-50% with sustained semaglutide or tirzepatide therapy.
Nevada-specific context
Nevada has telehealth access concentrated in Las Vegas, Henderson, Reno metros, with additional reach to North Las Vegas and Sparks. University Medical Center of Southern Nevada, Renown Health is the largest in-state academic medical center for endocrine + obesity-medicine specialty consults. The state health authority publishes prescribing + coverage updates at dhhs.nv.gov.
Nevadatelehealth & pricing rules
- • Nevada permits audio-only and asynchronous telehealth visits for GLP-1 care.
- • Nevada allows new-patient telehealth prescribing without a prior in-person visit.
- • Typical cash GLP-1 price in Nevada: ~$269/mo (compounded options often lower, brand higher).
State telehealth statutes change — verify current rules with your provider before booking.